Abstract
Using spatial modeling techniques, we highlight disparities in access to monoclonal antibodies (mAbs) used to treat COVID-19 patients. Fifteen million individuals in the United States must travel over 30 min to access mAbs. Areas with lower COVID-19 vaccination rates have worse access to essential COVID-19 therapeutics.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
